VAXX

Vaxxinity Inc

VAXX, USA

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.

https://www.vaxxinity.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
VAXX
stock
VAXX

Scientists discover how Covid shots cause deadly heart damage... as officials launch probe into vaccine-linked deaths Daily Mail

Read more →
VAXX
stock
VAXX

The hottest cancer vaccine companies you should know about Labiotech.eu

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2024-03-31)

Rating:

STRONG BUY

Target Price:

$15

Analyst Picks

Strong Buy

1

Buy

0

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2024-03-31)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.00

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-84.96 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-25.71 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very Low

2.30

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 15.11% of the total shares of Vaxxinity Inc

1.

Adage Capital Partners Gp LLC

(2.3669%)

since

2023/12/31

2.

BlackRock Inc

(2.1412%)

since

2023/12/31

3.

Vanguard Group Inc

(1.8863%)

since

2023/12/31

4.

Vanguard Total Stock Mkt Idx Inv

(1.1746%)

since

2024/04/30

5.

Prime Movers Lab LLC

(0.9483%)

since

2023/12/31

6.

iShares Russell 2000 ETF

(0.7833%)

since

2024/04/30

7.

Geode Capital Management, LLC

(0.6643%)

since

2023/12/31

8.

State Street Corporation

(0.6306%)

since

2023/12/31

9.

Vanguard Institutional Extnd Mkt Idx Tr

(0.4434%)

since

2024/04/30

10.

Fidelity Small Cap Index

(0.3094%)

since

2024/02/29

11.

Bank of America Corp

(0.2827%)

since

2023/12/31

12.

iShares Russell 2000 Growth ETF

(0.2781%)

since

2024/04/30

13.

Northern Trust Corp

(0.2639%)

since

2023/12/31

15.

Creative Planning Inc

(0.2249%)

since

2023/12/31

16.

Morgan Stanley - Brokerage Accounts

(0.1819%)

since

2023/12/31

17.

Bridgeway Capital Management, LLC

(0.1808%)

since

2023/12/31

18.

Bridgeway Ultra-Small Company Market

(0.1709%)

since

2024/03/31

19.

Fidelity Extended Market Index

(0.1674%)

since

2024/03/31

20.

Vanguard Russell 2000 ETF

(0.1252%)

since

2024/04/30

21.

Pathstone Holdings LLC

(0.1214%)

since

2023/12/31

22.

Pathstone Family Office, LLC

(0.1214%)

since

2023/09/30

23.

SCOGGIN LLC

(0.1183%)

since

2023/09/30

24.

NT R2000 Growth Index Fund - NL

(0.1009%)

since

2023/12/31

25.

NT R2000 Index Fund - NL

(0.0969%)

since

2024/03/31

26.

Bank of New York Mellon Corp

(0.0952%)

since

2023/12/31

27.

Charles Schwab Investment Management Inc

(0.0949%)

since

2023/12/31

28.

BlackRock Extended Mkt Composite

(0.0912%)

since

2023/09/30

29.

BlackRock Extended Equity Market K

(0.0787%)

since

2024/03/31

30.

NT R2000 Index Fund - DC - NL - 2

(0.0769%)

since

2024/03/31

31.

Schwab Small Cap Index

(0.0768%)

since

2024/04/30

32.

iShares Micro-Cap ETF

(0.072%)

since

2024/04/30

33.

Northern Trust Russell 2000 Growth Index

(0.0672%)

since

2024/03/31

34.

NT R2000 Growth Index Fund - L

(0.0672%)

since

2023/12/31

35.

IEQ CAPITAL, LLC

(0.0657%)

since

2023/12/31

36.

BlackRock Russell 2500â„¢ Index F

(0.0628%)

since

2024/03/31

37.

iShares Russell 2000 Small-Cap Idx Instl

(0.0627%)

since

2024/03/31

38.

McAdam, LLC

(0.0618%)

since

2024/03/31

39.

Barclays PLC

(0.0461%)

since

2023/12/31

40.

Nuveen Asset Management, LLC

(0.0458%)

since

2023/12/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

0

EPS Estimate

0

EPS Difference

0

Surprise Percent

null%

Investing Fit Scorecard

(Last Updated 2024-03-31)

Deep Value
Potential Value Candidate(5.5)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
No Clear Moat(2.8)
GARP
Not Attractive for GARP(0.5)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Strong Net-Net(8)
Quality
Low Quality Business(1.5)
Value
Fair Value(4)

Income Statement

(Last Updated 2024-03-31)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2024-03-31)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2024-03-31)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.